Neuralink

Neuralink said its clinical trials worldwide now include 21 participants. After making surgical and postoperative changes in response to thread retraction in the first recipient, the company reported higher signal quality in 18 of the next 20 participants. The figures come from a company update rather than a peer-reviewed clinical report.

Neuralink said thread retraction in its first PRIME participant temporarily reduced BCI performance before the threads stabilized and performance recovered. For the second implant, the team reduced brain motion during surgery and narrowed the gap between the implant and the brain surface. The company reported no thread retraction in the second participant at the time, but it did not publish channel-attrition rates or a formal interim safety report.